Koninklijke Philips N.V. NY Registry Shares Stock 12‑Month Price Target Raised to $30.99, Implies 9% Upside

Koninklijke Philips N.V. NY Registry Shares' average price target increased from $30.81 to $30.99 by 19 analysts, with a range of $24.63 to $43.32. This implies a 9% upside from the Nov. 3 closing price. The consensus rating remains 'Buy' among 22 analysts.

Original reporting
Published Nov 4, 2026, 4:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 4:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Koninklijke Philips N.V. NY Registry Shares Stock 12‑Month Price Target Raised to $30.99, Implies 9% Upside — source image
Decision brief

The 30-second read

$PHGBullishLow
01

Why it matters

A higher target can attract short‑term buying, but without fresh fundamentals the effect may be muted.

02

Market read

Analyst target revision provides modest bullish cue; limited trading relevance.

03

What to watch

No new earnings or product news; the change reflects analyst sentiment only.

Relevance 5/10Novelty 5/10Timing: today

Background

The article reports a consensus analyst price‑target increase for Philips (PHG) based on recent estimates.

Company-level read

Ticker impact

$PHGBullishMedium confidence
Context

Analyst consensus price target for Philips was raised to $30.99, implying ~9% upside.

Expected impact

potential upward pressure as investors price in the higher target

Evidence & confidence

Analyst target lifts often lead to short-term buying interest, but the move is modest.

Market effects

Minor positive signal for the health‑tech sector.

Limited to markets tracking Philips ADR.

Low global impact.

Counterpoint

Target raise may already be priced in; limited upside.

Key entities

  • Koninklijke Philips N.V.

    Dutch health‑technology firm, US ADR ticker PHG.

Related articles

$PHGMedAI 8/10

Philips: 3 Key Takeaways for Long-Term Investors

Philips reported an 8% increase in equipment order intake for Q3 2026, driven by health systems prioritizing long-term value over price. The company is shifting to subscription models like EMaaS, which doubled year-over-year revenue. Cost-cutting measures saved EUR 427 million year-to-date, offsetting inflation. Full-year order intake is up 4%, with comparable sales growth at 3.5%.

$PHGMed

Koninklijke Philips NV (PHG) Q3 2026 Earnings Call Highlights: Margin Expansion, Strong

Koninklijke Philips NV (PHG) reported Q3 2026 earnings, highlighting margin expansion and strong order momentum in North America and international regions. Connected Care orders declined mid-single-digits but management expressed confidence in the segment. Personal Health saw 8% comparable sales growth. The company raised full-year guidance to the lower end of high single-digit range.

$PHGMedAI 8/10

What Koninklijke Philips (PHG) Said on Its Q3 Earnings Call

Koninklijke Philips (PHG) reported Q3 results with flat Diagnosis & Treatment sales, driven by declines in China and ultrasound shipments. Connected Care sales grew 5%, while Personal Health saw 8% growth. The company reaffirmed its 2026 outlook, citing productivity savings and margin improvements. Adjusted EPS rose over 10% to €0.40. Philips expects ultrasound sales recovery to support momentum into 2027.

$PHGMedAI 8/10

KONINKLIJKE PHILIPS NV (PHG): Financial results for Q3 2026

KONINKLIJKE PHILIPS NV (PHG) furnished an SEC Form 6-K — earnings release. Yes ☐ No ☒ Name and address of person authorized to receive notices and communications from the Securities and Exchange Commission: M.J. van Ginneken Koninklijke Philips N.V. Prinses Irenestraat 59 1077 WV Amsterdam – The Netherlands This report comprises a copy of the following

$PHGHigh

Why is Koninklijke Philips stock rallying today?

Koninklijke Philips (PHG) stock rose 5.6% to €25.90 after Q3 2026 results beat expectations, with 8% order intake growth and 3% sales growth. Adjusted EBITA margin expanded to 13.0%, and free cash flow reached €384M. The company reaffirmed its annual outlook, despite a net income drop due to a €288M legal provision. Analysts maintained a 'Hold' consensus.